Proceedings · Session S-795 · filed November 19, 2026
Research Funding & PolicySession paper
Trump Withdraws Overton FDA Nomination, Extending Agency Leadership Gap
Trump pulled Heidi Overton's FDA nomination one day before a HELP Committee vote, extending a vacuum that began when Makary resigned in May and complicating sponsor review timelines.
By Sophie Lindqvist3 min read548 words
Summary
- Trump withdrew Heidi Overton's FDA commissioner nomination on November 18, 2026, one day before a Senate HELP Committee vote.
- The FDA has lost more than 4,500 staff, about 20% of its workforce, over the past year.
- The National Priority Voucher pilot has issued no vouchers since May 2026.
- The White House is weighing Senator Roger Marshall of Kansas as a replacement nominee.
- The commissioner post has been vacant since Marty Makary resigned in May 2026.
President Donald Trump withdrew Heidi Overton's nomination to lead the FDA on November 18, 2026, one day before a Senate HELP Committee vote she was at risk of losing, according to three people familiar with the matter who spoke to Reuters. The move leaves the commissioner's post vacant for a sponsor community already navigating an agency that has shed more than 4,500 staff — roughly 20% of its workforce — over the past year.
Republicans held only a one-vote advantage on the Health, Education, Labor and Pensions Committee, meaning a single Republican defection could have defeated her. Two of Reuters' sources said the cause was insufficient congressional support. The White House is now weighing Senator Roger Marshall of Kansas as a replacement nominee, according to two of those sources. Marshall, a former obstetrician, recently lost his reelection bid. FDA Deputy Commissioner for Food Kyle Diamantas continues to serve as acting commissioner.
How Did the Nomination Unravel?
The White House nominated Overton on August 19, 2026. A preventive medicine physician and deputy director of the White House Domestic Policy Council, she was tapped to fill a post vacant since former Commissioner Marty Makary resigned in May. At the time, PharmTech reported Senate confirmation was not guaranteed and that Diamantas had reportedly turned down the commissioner role more than once.
Support frayed after Republicans lost control of both the House and the Senate in this month's midterm elections. Several HELP Committee members lost their seats, including outgoing Chairman Bill Cassidy of Louisiana, a physician, along with Susan Collins and Marshall. Cassidy said he remained undecided on Overton and had previously criticized her involvement in administration efforts to roll back childhood vaccination.
She faced opposition from three directions:
- Vaccines. In August, Overton appeared with Trump at an event promoting an executive order calling for fewer federally recommended childhood vaccinations and for splitting the measles, mumps, and rubella shot into three separate injections. People familiar with the conversations said her support for that order unnerved several medical groups and career FDA officials.
- Mifepristone. Democrats criticized her stance on the abortion pill. The FDA is conducting a safety review of mifepristone and has said it will conclude by March 2027.
- Vaping. The nonpartisan advocacy group Health in Office campaigned against her nomination after she defended the FDA's May authorization of fruit-flavored vapes at her September confirmation hearing.
What Does the Vacuum Cost Sponsors?
The withdrawal prolongs leadership instability at an agency that has replaced the acting heads of both its drug and biologics review centers since Makary's departure.
The consequences are already visible in regulatory planning. Many of Makary's acceleration initiatives never went through formal rulemaking, leaving them open to reversal. The National Priority Voucher pilot, one such program, has issued no vouchers since May. Sponsors that built launch plans and inspection readiness around one- to two-month review timelines may now face conventional schedules.
A new nominee will go before a Senate that Republicans no longer control. Until a commissioner is confirmed, sponsors face continued uncertainty over review timelines, guidance priorities, and whether recently introduced programs survive at all.
For quality and regulatory teams, the practical implication is straightforward: submission planning may need to assume established review pathways until the agency's direction becomes clearer.
via pharmtech.com (Source)
Filed under
- fda-leadership
- drug-regulation
- review-timelines
- public-health-policy
- agency-staffing
More from Sophie Lindqvist
Show full bio
Correspondent covering money, funding and market shifts around research and development at Hypothesis Wire.
243 articles
References
- FDA Shelves Priority Voucher Pilot After 22 Drug Vouchers
- Democrats take Congress: scientists see 'a new day' for US research oversight
- McNutt Warns 100,000 Agency Staff Losses as White House Targets Peer Review
- Eric Cantor Returns to Washington — This Time on Pharma's Side
- Drug Pricing, Medicaid, and Research Funding Hang on Midterms